FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, I	D.C. 20549	
---------------	------------	--

BENEFICIAL OWNERSHIP

Check this box if no longer subject	STATEMENT OF CHANGES IN
to Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	Filed nursuant to Section 16(a) of the

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Betz Stephen F.					2. Issuer Name and Ticker or Trading Symbol Crinetics Pharmaceuticals, Inc. [CRNX]									k all app Direc	licable) tor	Ü	10% O	wner
(Last) (First) (Middle) C/O CRINETICS PHARMACEUTICALS, INC. 10222 BARNES CANYON ROAD, BLDG 2				3. Date of Earliest Transaction (Month/Day/Year) 02/01/2023									X	below)		below)		opeony
(Street) SAN DIEGO CA 92121 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indi Line) X	·				
	Table	I - Nor	า-Deriva	tive S	Secu	rities	Acq	uired	, Dis	posed of	, or E	Benef	icially	/ Own	ed			
Date				Exec if any	ecution Date, any		Transaction Dispos Code (Instr. 5)		Disposed C			4 and Secur Benef Owne		ties cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									v	Amount	(A) (D)	or Pr	ice	Transa	nsaction(s)			(111501.4)
Common Stock 02/01/2				2023				S ⁽¹⁾		3,126	Г	\$	19.59	59 64,689			D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
crivative conversion or Exercise (Month/Day/Year) Execution Date, if any (Month/Day/Year) Derivative Security			Code (8)	Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Date Expiration			Amour		Derivative Security (Instr. 5)		derivative Securities Beneficiall Owned Following Reported	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
	(Final Conversion or Exercise Price of Derivative	(First) (INETICS PHARMACEUTIARNES CANYON ROAD, EGO CA 9 (State) (Z Table Security (Instr. 3) Stock Tal 2. Conversion or Exercise Price of Derivative (Month/Day/Year)	(First) (Middle) INETICS PHARMACEUTICALS, ARNES CANYON ROAD, BLDG EGO CA 92121 (State) (Zip) Table I - Nor Security (Instr. 3) Stock Table II - 2. Conversion or Exercise Price of Derivative [Month/Day/Year) [Any Month/Month/Day/Year] [Any Month/Day/Year] Stock [Month/Day/Year] [Any Middle] 2. Conversion or Exercise Price of Derivative [Month/Day/Year] [Any Month/Mont	(First) (Middle) INETICS PHARMACEUTICALS, INC. ARNES CANYON ROAD, BLDG 2 EGO CA 92121 (State) (Zip) Table I - Non-Deriva Security (Instr. 3) 2. Transac Date (Month/Da Stock Table II - Derivati (e.g., pu 2. Conversion or Exercise Price of Derivative (Month/Day/Year) [Month/Day/Year]	(First) (Middle) (INETICS PHARMACEUTICALS, INC. ARNES CANYON ROAD, BLDG 2 EGO CA 92121 (State) (Zip) Table I - Non-Derivative Security (Instr. 3) Stock Table II - Derivative Security (Month/Day/Year) 2. Transaction Date (Month/Day/Year) Stock 2. Transaction Date (Instr. 3) 3. Date (Month/Day/Year) 3. Date (Month/Day/Year) 4. Transaction Date (Month/Day/Year) Stock 2. Market Carlot (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Deemed Execution Date, if any (Month/Day/Year) (Month/Day/Year) 4. Transaction Date (Month/Day/Year) 3. Date (Month/Day/Year)	(First) (Middle) INETICS PHARMACEUTICALS, INC. ARNES CANYON ROAD, BLDG 2 EGO CA 92121 (State) (Zip) Table I - Non-Derivative Security (Instr. 3) 2. Transaction Date (Month/Day/Year) Stock Table II - Derivative Security (e.g., puts, calls, v. (Month/Day/Year) 2. Conversion or Exercise Price of Derivative Price of Der	Crinetics Pharmaceuricals, INC. ARNES CANYON ROAD, BLDG 2 EGO CA 92121 (State) (Zip) Table I - Non-Derivative Securities (Month/Day/Year) Security (Instr. 3) 2. Transaction Date (Month/Day/Year) Table II - Derivative Securities (e.g., puts, calls, warrance of Derivative Security (Month/Day/Year) 2. Table II - Derivative Securities (e.g., puts, calls, warrance of Derivative Security (Month/Day/Year) 3. Date of Earliest 02/01/2023 4. If Amendment, 2. Transaction Date (Le.g., puts, calls, warrance of Derivative Security (e.g., puts, calls, warrance of Derivative Security (Month/Day/Year) 3. Date of Earliest 02/01/2023 4. If Amendment, 2. Transaction Date (Le.g., puts, calls, warrance of Derivative Securities (e.g., puts, calls, warrance of Derivative Security (Month/Day/Year) 3. Date of Earliest 02/01/2023 4. If Amendment, Crinetics Pharmaceurical (Pharmaceurical Securities (Pharmaceur	Crinetics Pharma Crinetics Pharma Crinetics Pharma Crinetics Pharma Crinetics Pharma 3. Date of Earliest Trans 02/01/2023 4. If Amendment, Date of Execution Date of Execution Date, if any (Month/Day/Year) Table II - Derivative Securities Acques. Conversion or Exercise Price of Derivative Security Security Security Security Conversion or Exercise Price of Derivative Security Conversion or Exercise Price of Derivative Security Conversion or Exercise Price of Derivative Security Conversion or Exercise Price of Date (Month/Day/Year) Conversion	Crinetics Pharmaceuti (First) (Middle) INETICS PHARMACEUTICALS, INC. ARNES CANYON ROAD, BLDG 2 EGO CA 92121 (State) (Zip) Table I - Non-Derivative Securities Acquired Execution Date (Month/Day/Year) (Month/Day/Year) 2A. Deemed Execution Date if any (Month/Day/Year) (Conversion or Exercise Price of Derivative Security 2. Transaction Date (e.g., puts, calls, warrants, optio) Table II - Derivative Securities Acquired, I (any (Month/Day/Year)) 3. Date of Earliest Transaction (02/01/2023) 4. If Amendment, Date of Original Acquired (A) (A) (B) (B) (B) (B) (B) (B) (B) (B) (B) (B	Crinetics Pharmaceuticals (First) (Middle) INETICS PHARMACEUTICALS, INC. ARNES CANYON ROAD, BLDG 2 EGO CA 92121 (State) (Zip) Table I - Non-Derivative Securities Acquired, Dispersivative Securities Acquired (Month/Day/Year) Security (Instr. 3) 2. Transaction Date (Month/Day/Year) Stock Table II - Derivative Securities Acquired, Dispressivative Securities Acquired, Dispressivative Securities Acquired, Dispressivative Securities Acquired (Pointstr. 3) Table II - Derivative Securities Acquired, Dispressivative Securities Acquired (Pointstr. 3) Table II - Derivative Securities Acquired (Pointstr. 3) A. Date of Earliest Transaction (Month O2/01/2023) 3. Transaction Date (Month/Day/Year) Code (Instr. 3) Stock Table II - Derivative Securities Acquired (Pointstr. 3) A. Deemed Execution Date, if any (Month/Day/Year) Stock Table II - Derivative Securities Acquired (Pointstr. 3) A. Deemed Execution Date, if any (Month/Day/Year) Stock Derivative Securities Acquired (Pointstr. 3) A. Date of Earliest Transaction (Month O2/01/2023) A. If Amendment, Date of Original Files A. Transaction Code (Instr. 8) Code V Stock Derivative Securities Acquired (Pointstr. 3) Code (Instr. 3) Date of Date Exercities Acquired (Pointstr. 3) A. Date of Earliest Transaction (Month Date of Original Files A. If Amendment, Date of Orig	Crinetics Pharmaceuticals, Inc. [Crinet	Crinetics Pharmaceuticals, Inc. [CRNX Crinetics Pharmaceuticals, Inc. CRNX Crinetics Pharmaceuticals, Inc. CRNX Crinetics Pharmaceuticals, Inc. CRNX Crinetics Pharmaceuticals, Inc. CRNX Crinetics Pharmaceuticals, Inc. CRNX Crinetics Pharmaceuticals, Inc. CRNX Crinetics Pharmaceuticals, Inc. CRNX Crinetics Pharmaceuticals, Inc. CRNX Crinetics Pharmaceuticals, Inc. CRNX Crinetics Pharmaceuticals, Inc. CRNX Crinetics Pharmaceuticals, Inc. CRNX Crinetics Pharmaceuticals, Inc. CRNX Crinetics Pharmaceuticals, Inc. CRNX Code Inc.	(First) (Middle) INETICS PHARMACEUTICALS, INC. ARNES CANYON ROAD, BLDG 2 EGO CA 92121 (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Benefic Case (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Stock 02/01/2023 S(1) 3,126 D \$ Table II - Derivative Securities Acquired, Disposed of, or Benefic Code (Instr. 8) (E. G. Date Securities Acquired, Disposed of, or Benefic (e.g., puts, calls, warrants, options, convertible securities Price of Derivative Securities Acquired, Disposed of, or Benefic (e.g., puts, calls, warrants, options, convertible securities Acquired (A) or Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 2. Transaction Date (Month/Day/Year) 3. Date of Earliest Transaction (Month/Day/Year) 4. Securities Acquired, Disposed of, or Benefic (e.g., puts, calls, warrants, options, convertible securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 2. Transaction Date (Month/Day/Year) 3. Date of Earliest Transaction (Month/Day/Year) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Number (6. Date Exercisable and Expiration Date (Month/Day/Year) 6. Date Expiration Date (Month/Day/Year) 8. Date Demod (Month	Crinetics Pharmaceuticals, Inc. [CRNX] (First) (Middle) INETICS PHARMACEUTICALS, INC. ARNES CANYON ROAD, BLDG 2 EGO CA 92121 (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Security (Instr. 3) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) Table II - Derivative Securities Acquired, Disposed of, or Beneficially (Month/Day/Year) Table II - Derivative Securities Acquired, Disposed of, or Beneficially (e.g., puts, calls, warrants, options, convertible securities) 2. Transaction Code (Instr. 8) Table II - Derivative Securities Acquired, Disposed of, or Beneficially (e.g., puts, calls, warrants, options, convertible securities) 2. Transaction Code (Instr. 8) Table II - Derivative Securities Acquired, Disposed of, or Beneficially (e.g., puts, calls, warrants, options, convertible securities) 2. Transaction Code (Instr. 8) Table II - Derivative Securities Acquired (A) or Disposed of, or Beneficially (e.g., puts, calls, warrants, options, convertible securities) 2. Transaction Date (Instr. 8) A. Deemed Execurities (Month/Day/Year) A. Deemed Execurities (Month/Day/Year	Crinetics Pharmaceuticals, Inc. [CRNX] Crinetics Pharmaceuticals, Inc. [CRNX] Crinetics Pharmaceuticals, Inc. [CRNX] Security (Instr. 3) Crinetics Pharmaceuticals, Inc. [CRNX] Security (Instr. 3) Crinetics Pharmaceuticals, Inc. [CRNX] Security (Instr. 3) Crinetics Pharmaceuticals, Inc. [CRNX] Security (Instr. 4) Crinetics Pharmaceuticals, Inc. [CRNX] Security (Instr. 5) Crinetics Pharmaceuticals, Inc. [CRNX] Security (Instr. 6) Code (Instr. 6) Co	Crinetics Pharmaceuticals, Inc. CRNX Check all applicable Director	Crinetics Pharmaceuticals, Inc. CRNX Check all applicable Director Officer (give title below)	Crinetics Pharmaceuticals, Inc. CRNX Check all applicable) Director 10% O Ordiforer (give title below) Chief Scientific Officer 10% O Ordiforer (give title below) Chief Scientific Officer 10% O Ordiforer (give title below) Chief Scientific Officer 10% O Ordiforer (give title below) Chief Scientific Officer 10% O Ordiforer (give title below) Chief Scientific Officer 10% O Ordiforer (give title below) Chief Scientific Officer 10% O Ordiforer (give title below) Chief Scientific Officer 10% O Ordiforer (give title below) Chief Scientific Officer 10% O Ordiforer (give title below) Chief Scientific Officer 10% O Ordiforer (give title below) Chief Scientific Officer 10% O Ordiforer (give title below) Chief Scientific Officer 10% O Ordiforer (give title below) Chief Scientific Officer 10% O Ordiforer (give title below) Chief Scientific Officer 10% O Ordiforer (give title Driver (give title below) Chief Scientific Officer 10% O Ordiforer (give title Driver (give title

Explanation of Responses:

1. The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

Remarks:

/s/ Marc Wilson, as attorney-

** Signature of Reporting Person

in-fact

02/03/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.